Rheumatology Advisor—December 8, 2017
Rheumatology Advisor interviewed Allan Gibofsky, MD, rheumatologist at HSS, about his recent study on osteoarthritis treatment at the 2017 ACR/ARHP Annual Meeting.
The study examined the effects of inhibiting the Wnt pathway, a series of signaling molecules that are involved with bone growth, on osteoarthritis patients.
"It is thought that activation of the Wnt pathway may be important in the resulting degeneration of cartilage and bone that's seen in osteoarthritis," said Dr. Gibofsky.
"Consequently, if one can find a way of inhibiting the mechanism that leads to cartilage and bone destruction, one would actually have a way of providing disease modification rather than just symptom modification," he added.
During his research, Dr. Gibofsky gave osteoarthritis patients an inhibitor and found that patients experienced an improvement in function as well as a reduction in pain.
"Again, I want to significantly point out that this is an early study — it's a proof of concept study, there were small numbers of patients — yet it is encouraging in that the results of this study will allow us to go forward and treat more patients with this very significant and very disabling disease," noted Dr. Gibofsky.
Watch the full interview at rheumatologyadvisor.com